Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study ☆
Titel:
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study ☆
Auteur:
Graff, J.N. Burotto, M. Fong, P.C. Pook, D.W. Zurawski, B. Manneh Kopp, R. Salinas, J. Bylow, K.A. Kramer, G. Ratta, R. Kwiatkowski, M. Retz, M. Kwak, C. Arranz Arija, J.A. Gurney, H. Matsubara, N. Villanueva, L. Todenhöfer, T. Liang, L.W. Todoric, J. Imai, K. Stenzl, A.
Verschenen in:
Annals of oncology
Paginering:
Jaargang 36 () nr. 8 pagina's 976-987
Jaar:
2025
Inhoud:
Uitgever:
Merck & Co., Inc., Rahway, NJ, USA and its affiliates, The Author(s)